Abaloparatide
- TRADE NAME: Tymlos (Radius Health)
- INDICATIONS: Osteoporosis in postmenopausal women
- CLASS: Parathyroid hormone analog
- HALF-LIFE: <2 hours
FDA APPROVAL DATE: 04/28/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
Not indicated for use in females of reproductive potential
RISK OF OSTEOSARCOMA
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric